Obviously if the stock price makes it's way to upl
Post# of 72447
(Total Views: 299)
Posted On: 08/25/2018 12:33:10 PM
Obviously if the stock price makes it's way to uplisting with new all time highs ($5+), then a $2B buyout is probably no longer in the cards. We would likely have a fresh Aspire contract if needed and a market to sell into.
Does a $10-20M upfront + trial costs on B-OM get us to an uplist? Granted, that combined with a 40%PASI75 on Prurisol would probably do so as a deal/sale of P would be assured at that point. What if P disappoints? Then we have to wait another couple years to get the result of B-OM phase 3 while trickling sales to Aspire (would they even fund us going into this plan?) to get another Kevetrin trial going?
I don't think anyone expected it would be 2019 before a Prurisol phase 3 (or 505b NDA application) would begin. It's a question of timelines and how much time one wants to spend in the risk zone.
I think some are overestimating Leo's hand at the bargaining table. The terms of the Aspire sales have deteriorated considerably this year. Advancing a drug on our own would be very painful to current shareholders and there is no gaurentee of success. A $2 billion buyout would be a huge and gaurenteed success for every shareholder.
I'm optimistic on Prurisol but the reason I'm holding here is because I believe that in the worst of situations we could sell the company for $100M+ (above the current market cap) just for B-ABSSSI. This is not where I thought we would be as we barrel through the second half of 2018.
Does a $10-20M upfront + trial costs on B-OM get us to an uplist? Granted, that combined with a 40%PASI75 on Prurisol would probably do so as a deal/sale of P would be assured at that point. What if P disappoints? Then we have to wait another couple years to get the result of B-OM phase 3 while trickling sales to Aspire (would they even fund us going into this plan?) to get another Kevetrin trial going?
I don't think anyone expected it would be 2019 before a Prurisol phase 3 (or 505b NDA application) would begin. It's a question of timelines and how much time one wants to spend in the risk zone.
I think some are overestimating Leo's hand at the bargaining table. The terms of the Aspire sales have deteriorated considerably this year. Advancing a drug on our own would be very painful to current shareholders and there is no gaurentee of success. A $2 billion buyout would be a huge and gaurenteed success for every shareholder.
I'm optimistic on Prurisol but the reason I'm holding here is because I believe that in the worst of situations we could sell the company for $100M+ (above the current market cap) just for B-ABSSSI. This is not where I thought we would be as we barrel through the second half of 2018.
(1)
(4)